Pre-existing anti-inflammatory immune conditions influence early antibody avidity and isotype profile following Comirnaty® vaccination in mice

Autores
Castillo, Mariangeles; Miraglia, Maria Cruz; Mansilla, Florencia Celeste; Randazzo, Cecilia Paola; Bentancor, Leticia Veronica; Freire, Teresa; Capozzo, Alejandra
Año de publicación
2025
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background/Objectives: Vaccine immunogenicity is often suboptimal in vulnerable populations such as the elderly, infants, and individuals in low- and middle-income countries. One contributing factor may be pre-existing immunomodulatory conditions, including helminth infections. This study investigates the impact of Fasciola hepatica (F. hepatica) derived molecules on the early humoral response to the COVID-19 mRNA vaccine Comirnaty® in a mouse model. Methods: BALB/c mice were pretreated with a F. hepatica protein extract (FH) or complete Freund’s adjuvant (CFA) prior to vaccination. Cytokine production and antibody responses were assessed at 0, 14, and 21 days post-vaccination (dpv) through serum analysis and ex vivo splenocyte stimulation with the SARS-CoV-2 receptor-binding domain (RBD) or LPS. Results: At 0 dpv, FH-treated mice showed increased serum IL-10, while CFA treatment induced IL-12. FH- but not CFA-treated splenocytes secreted IL-10 upon RBD or LPS stimulation. At 21 dpv, FH-treated mice lacked IFN-γ production but maintained IL-10 and showed elevated IL-4, consistent with a Th2-skewed profile. Although total anti-RBD IgG levels were similar between groups, FH-treated mice exhibited reduced IgG avidity and a higher IgG1/IgG2 ratio. CFA-treated mice showed delayed avidity maturation. Conclusions: Prior exposure to F. hepatica antigens can modulate the early immune response to Comirnaty®, affecting both cellular activation and antibody quality. This altered response may reflect a reduced early protective capacity of the vaccine, which might need to be considered when designing or evaluating vaccination strategies using mRNA vaccines in helminth-endemic regions.
Instituto de Virología
Fil: Castillo, Mariangeles. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Castillo, Mariangeles. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Miraglia, María Cruz. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Miraglia, María Cruz. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Mansilla, Florencia Celeste. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Mansilla, Florencia Celeste. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Randazzo, Cecilia Paola. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Randazzo, Cecilia Paola. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Bentancor, Leticia Veronica. Universidad Nacional de José Clemente Paz. Instituto de Estudios para el Desarrollo Productivo y la Innovación; Argentina
Fil: Freire, Teresa. Universidad de La República. Facultad de Medicina. Unidad Académica Inmunobiología. Laboratorio de Inmunomodulación y Vacunas; Uruguay
Fil: Capozzo, Alejandra. Universidad Abierta Interamericana. Centro de Altos Estudios en Ciencias Humanas y de la Salud (CAECIHS); Argentina
Fil: Capozzo, Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fuente
Vaccines 13 (7) : 677 (July 2025)
Materia
Immunomodulation
Immune Response
Antiinflammatory Agents
Antibodies
Isotypes
Vaccination
Mice
Inmunomodulación
Respuesta Inmunológica
Antinflamatorios
Anticuerpos
Isotipo
Vacunación
Ratón
Fasciola hepatica
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/23059
Acceder
id INTADig_3a0e513c73393a37d6d0e5d844de0853
oai_identifier_str oai:localhost:20.500.12123/23059
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Pre-existing anti-inflammatory immune conditions influence early antibody avidity and isotype profile following Comirnaty® vaccination in miceCastillo, MariangelesMiraglia, Maria CruzMansilla, Florencia CelesteRandazzo, Cecilia PaolaBentancor, Leticia VeronicaFreire, TeresaCapozzo, AlejandraImmunomodulationImmune ResponseAntiinflammatory AgentsAntibodiesIsotypesVaccinationMiceInmunomodulaciónRespuesta InmunológicaAntinflamatoriosAnticuerposIsotipoVacunaciónRatónFasciola hepaticaBackground/Objectives: Vaccine immunogenicity is often suboptimal in vulnerable populations such as the elderly, infants, and individuals in low- and middle-income countries. One contributing factor may be pre-existing immunomodulatory conditions, including helminth infections. This study investigates the impact of Fasciola hepatica (F. hepatica) derived molecules on the early humoral response to the COVID-19 mRNA vaccine Comirnaty® in a mouse model. Methods: BALB/c mice were pretreated with a F. hepatica protein extract (FH) or complete Freund’s adjuvant (CFA) prior to vaccination. Cytokine production and antibody responses were assessed at 0, 14, and 21 days post-vaccination (dpv) through serum analysis and ex vivo splenocyte stimulation with the SARS-CoV-2 receptor-binding domain (RBD) or LPS. Results: At 0 dpv, FH-treated mice showed increased serum IL-10, while CFA treatment induced IL-12. FH- but not CFA-treated splenocytes secreted IL-10 upon RBD or LPS stimulation. At 21 dpv, FH-treated mice lacked IFN-γ production but maintained IL-10 and showed elevated IL-4, consistent with a Th2-skewed profile. Although total anti-RBD IgG levels were similar between groups, FH-treated mice exhibited reduced IgG avidity and a higher IgG1/IgG2 ratio. CFA-treated mice showed delayed avidity maturation. Conclusions: Prior exposure to F. hepatica antigens can modulate the early immune response to Comirnaty®, affecting both cellular activation and antibody quality. This altered response may reflect a reduced early protective capacity of the vaccine, which might need to be considered when designing or evaluating vaccination strategies using mRNA vaccines in helminth-endemic regions.Instituto de VirologíaFil: Castillo, Mariangeles. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Castillo, Mariangeles. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Miraglia, María Cruz. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Miraglia, María Cruz. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Mansilla, Florencia Celeste. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Mansilla, Florencia Celeste. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Randazzo, Cecilia Paola. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Randazzo, Cecilia Paola. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Bentancor, Leticia Veronica. Universidad Nacional de José Clemente Paz. Instituto de Estudios para el Desarrollo Productivo y la Innovación; ArgentinaFil: Freire, Teresa. Universidad de La República. Facultad de Medicina. Unidad Académica Inmunobiología. Laboratorio de Inmunomodulación y Vacunas; UruguayFil: Capozzo, Alejandra. Universidad Abierta Interamericana. Centro de Altos Estudios en Ciencias Humanas y de la Salud (CAECIHS); ArgentinaFil: Capozzo, Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaMDPI2025-07-17T12:15:05Z2025-07-17T12:15:05Z2025-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/23059https://www.mdpi.com/2076-393X/13/7/6772076-393Xhttps://doi.org/10.3390/vaccines13070677Vaccines 13 (7) : 677 (July 2025)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-10-16T09:32:24Zoai:localhost:20.500.12123/23059instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-10-16 09:32:25.177INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Pre-existing anti-inflammatory immune conditions influence early antibody avidity and isotype profile following Comirnaty® vaccination in mice
title Pre-existing anti-inflammatory immune conditions influence early antibody avidity and isotype profile following Comirnaty® vaccination in mice
spellingShingle Pre-existing anti-inflammatory immune conditions influence early antibody avidity and isotype profile following Comirnaty® vaccination in mice
Castillo, Mariangeles
Immunomodulation
Immune Response
Antiinflammatory Agents
Antibodies
Isotypes
Vaccination
Mice
Inmunomodulación
Respuesta Inmunológica
Antinflamatorios
Anticuerpos
Isotipo
Vacunación
Ratón
Fasciola hepatica
title_short Pre-existing anti-inflammatory immune conditions influence early antibody avidity and isotype profile following Comirnaty® vaccination in mice
title_full Pre-existing anti-inflammatory immune conditions influence early antibody avidity and isotype profile following Comirnaty® vaccination in mice
title_fullStr Pre-existing anti-inflammatory immune conditions influence early antibody avidity and isotype profile following Comirnaty® vaccination in mice
title_full_unstemmed Pre-existing anti-inflammatory immune conditions influence early antibody avidity and isotype profile following Comirnaty® vaccination in mice
title_sort Pre-existing anti-inflammatory immune conditions influence early antibody avidity and isotype profile following Comirnaty® vaccination in mice
dc.creator.none.fl_str_mv Castillo, Mariangeles
Miraglia, Maria Cruz
Mansilla, Florencia Celeste
Randazzo, Cecilia Paola
Bentancor, Leticia Veronica
Freire, Teresa
Capozzo, Alejandra
author Castillo, Mariangeles
author_facet Castillo, Mariangeles
Miraglia, Maria Cruz
Mansilla, Florencia Celeste
Randazzo, Cecilia Paola
Bentancor, Leticia Veronica
Freire, Teresa
Capozzo, Alejandra
author_role author
author2 Miraglia, Maria Cruz
Mansilla, Florencia Celeste
Randazzo, Cecilia Paola
Bentancor, Leticia Veronica
Freire, Teresa
Capozzo, Alejandra
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Immunomodulation
Immune Response
Antiinflammatory Agents
Antibodies
Isotypes
Vaccination
Mice
Inmunomodulación
Respuesta Inmunológica
Antinflamatorios
Anticuerpos
Isotipo
Vacunación
Ratón
Fasciola hepatica
topic Immunomodulation
Immune Response
Antiinflammatory Agents
Antibodies
Isotypes
Vaccination
Mice
Inmunomodulación
Respuesta Inmunológica
Antinflamatorios
Anticuerpos
Isotipo
Vacunación
Ratón
Fasciola hepatica
dc.description.none.fl_txt_mv Background/Objectives: Vaccine immunogenicity is often suboptimal in vulnerable populations such as the elderly, infants, and individuals in low- and middle-income countries. One contributing factor may be pre-existing immunomodulatory conditions, including helminth infections. This study investigates the impact of Fasciola hepatica (F. hepatica) derived molecules on the early humoral response to the COVID-19 mRNA vaccine Comirnaty® in a mouse model. Methods: BALB/c mice were pretreated with a F. hepatica protein extract (FH) or complete Freund’s adjuvant (CFA) prior to vaccination. Cytokine production and antibody responses were assessed at 0, 14, and 21 days post-vaccination (dpv) through serum analysis and ex vivo splenocyte stimulation with the SARS-CoV-2 receptor-binding domain (RBD) or LPS. Results: At 0 dpv, FH-treated mice showed increased serum IL-10, while CFA treatment induced IL-12. FH- but not CFA-treated splenocytes secreted IL-10 upon RBD or LPS stimulation. At 21 dpv, FH-treated mice lacked IFN-γ production but maintained IL-10 and showed elevated IL-4, consistent with a Th2-skewed profile. Although total anti-RBD IgG levels were similar between groups, FH-treated mice exhibited reduced IgG avidity and a higher IgG1/IgG2 ratio. CFA-treated mice showed delayed avidity maturation. Conclusions: Prior exposure to F. hepatica antigens can modulate the early immune response to Comirnaty®, affecting both cellular activation and antibody quality. This altered response may reflect a reduced early protective capacity of the vaccine, which might need to be considered when designing or evaluating vaccination strategies using mRNA vaccines in helminth-endemic regions.
Instituto de Virología
Fil: Castillo, Mariangeles. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Castillo, Mariangeles. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Miraglia, María Cruz. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Miraglia, María Cruz. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Mansilla, Florencia Celeste. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Mansilla, Florencia Celeste. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Randazzo, Cecilia Paola. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Randazzo, Cecilia Paola. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Bentancor, Leticia Veronica. Universidad Nacional de José Clemente Paz. Instituto de Estudios para el Desarrollo Productivo y la Innovación; Argentina
Fil: Freire, Teresa. Universidad de La República. Facultad de Medicina. Unidad Académica Inmunobiología. Laboratorio de Inmunomodulación y Vacunas; Uruguay
Fil: Capozzo, Alejandra. Universidad Abierta Interamericana. Centro de Altos Estudios en Ciencias Humanas y de la Salud (CAECIHS); Argentina
Fil: Capozzo, Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Background/Objectives: Vaccine immunogenicity is often suboptimal in vulnerable populations such as the elderly, infants, and individuals in low- and middle-income countries. One contributing factor may be pre-existing immunomodulatory conditions, including helminth infections. This study investigates the impact of Fasciola hepatica (F. hepatica) derived molecules on the early humoral response to the COVID-19 mRNA vaccine Comirnaty® in a mouse model. Methods: BALB/c mice were pretreated with a F. hepatica protein extract (FH) or complete Freund’s adjuvant (CFA) prior to vaccination. Cytokine production and antibody responses were assessed at 0, 14, and 21 days post-vaccination (dpv) through serum analysis and ex vivo splenocyte stimulation with the SARS-CoV-2 receptor-binding domain (RBD) or LPS. Results: At 0 dpv, FH-treated mice showed increased serum IL-10, while CFA treatment induced IL-12. FH- but not CFA-treated splenocytes secreted IL-10 upon RBD or LPS stimulation. At 21 dpv, FH-treated mice lacked IFN-γ production but maintained IL-10 and showed elevated IL-4, consistent with a Th2-skewed profile. Although total anti-RBD IgG levels were similar between groups, FH-treated mice exhibited reduced IgG avidity and a higher IgG1/IgG2 ratio. CFA-treated mice showed delayed avidity maturation. Conclusions: Prior exposure to F. hepatica antigens can modulate the early immune response to Comirnaty®, affecting both cellular activation and antibody quality. This altered response may reflect a reduced early protective capacity of the vaccine, which might need to be considered when designing or evaluating vaccination strategies using mRNA vaccines in helminth-endemic regions.
publishDate 2025
dc.date.none.fl_str_mv 2025-07-17T12:15:05Z
2025-07-17T12:15:05Z
2025-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/23059
https://www.mdpi.com/2076-393X/13/7/677
2076-393X
https://doi.org/10.3390/vaccines13070677
url http://hdl.handle.net/20.500.12123/23059
https://www.mdpi.com/2076-393X/13/7/677
https://doi.org/10.3390/vaccines13070677
identifier_str_mv 2076-393X
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Vaccines 13 (7) : 677 (July 2025)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1846143591920959488
score 12.712165

Publicaciones similares